BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...he’s watching two other targeted oncology companies. SpringWorks...
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Jean-Marc Bellemin as CFO. He was EVP and CFO at Gritstone Oncology Inc. (NASDAQ:GRTS).SpringWorks...
...NALP3; CIAS1) – NLR family pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...setbacks for the oncology company. Shares of Spectrum fell 11% to $3.40.Jazz takes rights to SpringWorks’...
...including PF-04457845 from SpringWorks Therapeutics Inc. (NASDAQ:SWTX), and plans to develop the therapy for post-traumatic stress disorder. SpringWorks...
...withdrawal and fear extinction. Jazz will also assume obligations owed to Pfizer Inc. (NYSE:PFE), which spun out SpringWorks...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp. (NASDAQ:BPMC), Translate Bio Inc. (NASDAQ:TBIO) and SpringWorks...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...Bio Inc. (NASDAQ: VIE), which spun out of AstraZeneca plc (LSE:AZN; NYSE:AZN) in 2018, and SpringWorks...
...following its $172.6 million IPO in October, with a current valuation of about $1.5 billion. SpringWorks...
...later, this September, brought in $186.3 million in an IPO, at a $778.2 million valuation. SpringWorks...
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...γ secretase to inhibit NOTCH signaling are in the clinic. The most advanced, nirogacestat from SpringWorks...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...John Flavin, who will remain as an independent director. Sullivan was founder and president of SpringWorks...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...NASDAQ:STSA) 09/12/19 $82.5 $249.1 $249.2 0% 10x Genomics Inc. (NASDAQ:TXG) 09/12/19 $448.5 $3,718.6 $4,805.6 29% SpringWorks...
BioCentury | Sep 26, 2019
Emerging Company Profile

Edgewise: breaking away from dystrophin for muscular dystrophy

...VP who served as Edgewise’s COO before becoming CBO of rare disease and cancer spinout SpringWorks...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...NASDAQ:IGMS) has added $5 (31%) to $21 since going public on Sept. 17; shares of SpringWorks...
Items per page:
1 - 10 of 32
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...he’s watching two other targeted oncology companies. SpringWorks...
BioCentury | Dec 18, 2020
Management Tracks

Rim named CEO of Samsung Biologics as Sarepta unveils promotions; plus Coughlin, Iovance, SpringWorks and NodThera

...company Iovance Biotherapeutics Inc. (NASDAQ:IOVA) hired Jean-Marc Bellemin as CFO. He was EVP and CFO at Gritstone Oncology Inc. (NASDAQ:GRTS).SpringWorks...
...NALP3; CIAS1) – NLR family pyrin domain containing 3 Danielle Golovin Sarepta Therapeutics Inc. Iovance Biotherapeutics Inc. Gritstone Oncology Inc. SpringWorks...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...setbacks for the oncology company. Shares of Spectrum fell 11% to $3.40.Jazz takes rights to SpringWorks’...
...including PF-04457845 from SpringWorks Therapeutics Inc. (NASDAQ:SWTX), and plans to develop the therapy for post-traumatic stress disorder. SpringWorks...
...withdrawal and fear extinction. Jazz will also assume obligations owed to Pfizer Inc. (NYSE:PFE), which spun out SpringWorks...
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...Inc. (NASDAQ:BLUE), Surface Oncology Inc. (NASDAQ:SURF), Blueprint Medicines Corp. (NASDAQ:BPMC), Translate Bio Inc. (NASDAQ:TBIO) and SpringWorks...
BioCentury | Dec 20, 2019
Product Development

Pharma spinouts: a snapshot of where and how pharmas spin out their assets

...Bio Inc. (NASDAQ: VIE), which spun out of AstraZeneca plc (LSE:AZN; NYSE:AZN) in 2018, and SpringWorks...
...following its $172.6 million IPO in October, with a current valuation of about $1.5 billion. SpringWorks...
...later, this September, brought in $186.3 million in an IPO, at a $778.2 million valuation. SpringWorks...
BioCentury | Dec 17, 2019
Financial News

Cellestia plans Phase II for solid, blood cancers with $20M series B

...γ secretase to inhibit NOTCH signaling are in the clinic. The most advanced, nirogacestat from SpringWorks...
BioCentury | Dec 14, 2019
Company News

Management Tracks: Alector hires new president, COO and appoints R&D committee co-chairs; plus Pyxis, Translate Bio, Canaan, PMV, Janpix, Kiadis and more

...John Flavin, who will remain as an independent director. Sullivan was founder and president of SpringWorks...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...NASDAQ:STSA) 09/12/19 $82.5 $249.1 $249.2 0% 10x Genomics Inc. (NASDAQ:TXG) 09/12/19 $448.5 $3,718.6 $4,805.6 29% SpringWorks...
BioCentury | Sep 26, 2019
Emerging Company Profile

Edgewise: breaking away from dystrophin for muscular dystrophy

...VP who served as Edgewise’s COO before becoming CBO of rare disease and cancer spinout SpringWorks...
BioCentury | Sep 23, 2019
Financial News

Fall IPO flurry as biotechs ramp up listing timelines

...NASDAQ:IGMS) has added $5 (31%) to $21 since going public on Sept. 17; shares of SpringWorks...
Items per page:
1 - 10 of 32